Practice
Featured experience
Amazon.com $15 billion notes offering
We advised the underwriters on the offering
Circle $1.05 billion IPO
We are advising Circle on its IPO, the first IPO by a stablecoin issuer
Novartis $6 billion notes offering
We advised Novartis on the investment-grade debt offering
SailPoint $1.4 billion IPO
The shares are listed on the Nasdaq Global Select Market
BioNTech $500 million SEC-registered at-the-market offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by BioNTech SE of its…
Fujian Yango $175 million high-yield notes offering
Davis Polk advised the joint lead managers in connection with the Regulation S offering of $175 million principal…
Affimed $75 million SEC-registered at-the-market offering program
Davis Polk advised the sales agent in connection with the establishment of an SEC-registered at-the-market offering…
Intercontinental Exchange $894.4 million block trade
Davis Polk advised the underwriter in connection with a block trade of 9,180,569 shares of common stock of…
RemeGen HK$4 billion Hong Kong IPO
Davis Polk advised the underwriters in the initial public offering of RemeGen Co., Ltd. on the Hong Kong Stock Exchange and…
Yancoal International Resources $500 million senior guaranteed bond offering
Davis Polk advised the joint lead managers and joint bookrunners in connection with an issuance of $500 million Regulation S…
AngloGold Ashanti $700 million debt offering
Davis Polk advised the underwriters in connection with an SEC-registered offering of $700 million aggregate principal amount…
Bandwidth block trade
Davis Polk advised the underwriter in connection with a block trade of 663,394 shares of Class A common stock of Bandwidth…
Finance of America Funding $350 million senior notes offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by…
NovoCure $575 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by NovoCure Limited…